Polpharma strategic moves to buys a Pharma company in Kazakhstan

• Over the next 4 years, the pharmaceutical company plans to invest about $ 85 million in the upgrade of infrastructure, developing of technology and products standards of Khimpharm;

• Already this year, it is scheduled to begin the construction of a new production plant for pharmaceuticals;

• After the implementing of GMP Standards, Polpharma will transfer the full production of its own drugs for the Eastern Europe market to manufacturing plants in Shymkent.

Polpharma was founded in 1935 in Gdański and it is now a major Polish producer of medicine. The company’s products are present in almost 50 countries. The most important markets for Polpharma are those of Central and Eastern Europe, including Belarus, Ukraine, Kazakhstan, Azerbaijan and Uzbekistan. Approximately 60% of the international sales of drugs are generated today on the Russian market.

Weitere Informationen unter:
http://www.chameleon-pharma.com

  cis-und-cee-consulting, kazakhstan, russian-pharma, ukraine